Events Archives - Page 62 of 128

1 minute read

Events
News

BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO

June 2, 6:47 AM

BioNTech SE (NASDAQ:BNTX, &ldquo, BioNTech&rdquo, )) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody

BNTX

1 minute read

TScan Therapeutics Announces Upcoming Trial In Progress Poster Presentation At The 2023 American Society Of Clinical Oncology Annual Meeting On June 3, 2023; 8:00 am – 11:00 am CDT

By Happy Mohamed

June 1, 4:14 PM

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today

TCRX

2 minute read

Omeros Corporation Announces Late-Breaking Presentation Of OMS906 Data At The 2023 European Hematology Association Congress

By Happy Mohamed

June 1, 11:04 AM

– Late-breaking abstract detailing interim data from ongoing clinical trial of OMS906 in treatment-naïve PNH patients selected for June 11, 2023 oral presentation – Omeros Corporation (NASDAQ:OMER)

OMER

2 minute read

Reported Earlier, Panbela Announces Poster Presentation At Immunology Of Diabetes Society Meeting: Evaluating The Potential Of CPP-1X In Recent Onset Type 1 Diabetes

By Happy Mohamed

June 1, 9:47 AM

Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation

PBLA

1 minute read

Vistagen Presents Fasedienol Safety And Exploratory Efficacy Data From Phase 3 Open-Label Social Anxiety Disorder Study At American Society For Clinical Psychopharmacology Annual Meeting

By Happy Mohamed

June 1, 8:31 AM

Favorable long-term, open-label treatment data from nearly 500 patients in real-world setting suggest that patient-tailored, as-needed administrations of fasedienol over time were safe and well-tolerated Positive

VTGN

1 minute read

Aspira Women’s Health Announces The Publication Of Three Abstracts By The American Society Of Clinical Oncology Supporting The Clinical Utility Of OvaSuite Ovarian Cancer Risk Assessment Tests

By Happy Mohamed

May 31, 8:04 AM

- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, announced the online publication

AWH

2 minute read

Vistagen To Present Fasedienol Safety And Exploratory Efficacy Data From Phase 3 Open-Label Social Anxiety Disorder Study At American Society For Clinical Psychopharmacology Annual Meeting

By Happy Mohamed

May 30, 4:28 PM

Late-breaking poster presentation highlights long-term, open-label treatment data of as-needed intranasal administrations of fasedienol in real-world setting Vistagen (NASDAQ:VTGN), a late clinical-stage

VTGN

2 minute read

Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib’s Potential As A Targeted Treatment For KRASG12C-Mutated Advanced Solid Tumors At 2023 ASCO Annual Meeting

By Happy Mohamed

May 30, 4:01 PM

Data follows recent inclusion of Adagrasib in NCCN Guidelines for PDAC and CNS Cancers Additional Company Presentations Highlight Real-World Observations in Patients Living with Metastatic NSCLC and

MRTX

2 minute read

SAB Biotherapeutics To Present Novel Human IgG Platform With Data And Breakthrough Therapy And Fast-Track Designations For Influenza Treatment At BIO 2023 International Convention

By Happy Mohamed

May 30, 8:37 AM

SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG)

SABS

1 minute read

Morphogenesis, CohBar Announce Acceptance of Abstract For Poster Presentation At 2023 ASCO Meeting

By Benzinga Newsdesk

May 30, 8:06 AM

Details of the presentation are as follows:Title: Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinomaAbstract #:

CWBR